StockData
Sigyn Therapeutics, Inc. logo

Sigyn Therapeutics, Inc. (SIGY) company profile

SIGYOTCSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2025, quý kết thúc ngày Sep 30, 2025Last filing: 10-Q on Nov 14, 2025Score 0/30
$0.03+0.00 (0.00%)

Close on Oct 19, 2026Market cap $48.16KP/E –Yield –

About Sigyn Therapeutics

Surgical & Medical Instruments & Apparatus, SIC 3841

Sigyn Therapeutics, Inc. is a medical device company that develops extracorporeal blood purification technologies to address cancer and infectious disease disorders. The company’s portfolio includes platforms designed to enhance cancer treatments, including the ImmunePrep platform to optimize immunotherapeutic antibody delivery, ChemoPrep to improve chemotherapy delivery, and ChemoPure to lower treatment toxicity by removing off-target chemotherapy. Its lead candidate, Sigyn Therapy, is a single-use disposable device designed to extract pathogens, bacterial toxins, hepatic toxins, and inflammatory cytokines from blood plasma, targeting conditions such as viral infections, antibiotic-resistant bacteria, endotoxemia, and sepsis.

The company's principal executive offices are located in San Diego, California. Sigyn designs its therapies to deploy on existing worldwide hospital hemodialysis and continuous renal replacement therapy machine infrastructure. Its clinical development plan focuses on treating end-stage renal disease patients with endotoxemia and inflammation, while preclinical and animal evaluations have taken place in academic research facilities.

Summary of the business section of Sigyn Therapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
Sigyn Therapeutics, Inc.
Headquarters
Beverly Hills, CA
Address
9190 W Olympic Blvd # 263 90212
Phone
(619) 368-2000
Employees
4, Dec 31, 2024
Industry
Surgical & Medical Instruments & Apparatus
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Kreit & Chiu CPA LLP, Los Angeles, California

Stock & identifiers

Ticker
SIGY
Former tickers
RSAP until Apr 19, 2019; RGNP until May 31, 2017
Exchange
OTC
Shares outstanding
2M, Nov 14, 2025
Public float
$3.61M, Jun 30, 2024
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-40 reverse, Jan 31, 2024; 1-for-150 reverse, Nov 9, 2020
SEC CIK
1642159
CUSIP
82674U205
ISIN
US82674U2050
FIGI
BBG0099X6BP0
Share class FIGI
BBG0099X6BQ9
EIN
47-2573116

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

No recent ownership filings by officers or directors

Sigyn Therapeutics's leadership is listed in its proxy statement (Form DEF 14A).

Employees

Headcount reported in annual reports

“As of the date of this filing, we have 4 salaried employees, whose benefits include paid medical, dental, and vision coverage.”

Corporate history

Events identified from SEC filings

DateEventDetails
Jul 16, 2026DeregistrationTermination of SEC registration (Form 15)
Mar 31, 2026Late filingNotification of late filing
Aug 15, 2025Late filingNotification of late filing
May 15, 2025Late filingNotification of late filing
Mar 31, 2025Late filingNotification of late filing
Nov 15, 2024Late filingNotification of late filing
Aug 14, 2024Late filingNotification of late filing
Mar 31, 2021Late filingNotification of late filing
Oct 23, 2020Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Oct 23, 2020Name changeName changed from Reign Resources Corp to Sigyn Therapeutics, Inc.
May 12, 2020Name changeName changed from Reign Sapphire Corp to Reign Resources Corp
Jan 6, 2020Auditor changeChange in certifying accountant (8-K Item 4.01)
Jan 3, 2020Auditor changeChange in certifying accountant (8-K Item 4.01)
Jan 7, 2019Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Oct 17, 2018Auditor changeChange in certifying accountant (8-K Item 4.01)
Aug 7, 2017Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Apr 3, 2017Late filingNotification of late filing
Dec 2, 2016Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Nov 4, 2016Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Mar 14, 2016Auditor changeChange in certifying accountant (8-K Item 4.01)

See a number that looks wrong?